TransMedics director granted 2,922 RSUs
Lovell Stephanie reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Lovell Stephanie reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Stephanie Lovell received an equity award in the form of restricted stock units. On May 20, 2026, she was granted 2,922 shares of common stock at a price of $0.00 per share as a compensation-related award, not an open-market purchase. Each restricted stock unit represents a contingent right to receive one share of TransMedics common stock. Following this grant, Lovell directly holds 5,788 shares of the company’s common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,922 | $0.00 | $0.00 |
Footnotes (1)
- F1. Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Key Figures
Key Terms
restricted stock units ("RSUs") financial
contingent right financial
common stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did TransMedics (TMDX) disclose for Stephanie Lovell?
Was the recent TransMedics (TMDX) Form 4 an insider buy or a grant?
What are the terms of the 2,922 RSUs reported for TransMedics (TMDX)?
Does the TransMedics (TMDX) Form 4 indicate any stock sales by Stephanie Lovell?
AI-generated analysis. How Rhea-AI works. Not financial advice.